Insulin resistance: Current therapeutic approaches

Drugs of Today

Volumn 35, Issue 12, 1999, Pages 895-911

  Ramarao, Poduri ^a   Kaul, Chaman Lal ^a,b  

^a Department of Pharmaceutics   (India)

^b SAS Nagar   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CIGLITAZONE; DIGOXIN; ENGLITAZONE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; RANITIDINE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLINDNESS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ANALYSIS; DRUG MECHANISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; LIVER TOXICITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; RAT; REVIEW; STROKE;

EID: 0342514652     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. King, H., Aubert, R.E., Herman, W.H. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates and projections. Diabetes Care 1998, 21: 1414-31.
2. Turner, N.C., Clapham, J.C. Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities. Prog Drug Res 1988, 51: 33-94.
3. Consensus Development Conference on Insulin Resistance, 5-6 November 1997. American Diabetes Association. Diabetes Care 1998, 21: 310-4.
4. Himsworth, HP., Kerr, R.B. Insulin sensitive and insensitive types of diabetes mellitus. Clin Sci 1939, 4: 119-52.
5. Reaven, G.M., Brand, R.J., Chen, Y.D.I., Mathur, A.K., Goldine, I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993, 42: 1324-32.
6. Martin, B.C., Warram, J.H., Rusaner, B., Rich, S.S., Soaindner, J.S., Krowleski, A.S. Familial clustering of insulin sensitivity. Diabetes 1992, 41: 850-4.
7. Bloomgarden, Z.T. Insulin resistance and current concepts. Clin Ther 1998, 20: 216-31.
8. Vikramaki, A., Ueki, K., Kahn, C.R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999, 103: 931-43.
9. Yki-Jarvinen, H. Glucose toxicity. Endocr Rev 1992, 13: 415-31.
10. Kolterman, O.G., Inset, J., Saekow, M. et al. Mechanism of insulin resistance in human obesity: Evidence for receptor and post receptor defects. J Clin Invest 1979, 63: 939-46.
11. DeFronzo, R.A., Diebert, D., Hendler, R. et al. Insulin sensitivity and insulin binding in maturity onset diabetes. J Clin Invest 1980, 65: 1273-84.
12. Kolterman, O.G., Gray, R.S., Griffin, J. et al. Receptor and post receptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus. J Clin Invest 1981, 68: 957-69.
13. Olesky, J.M., Kolterman, O.G., Scarlett, J.A. Insulin action and resistance in obesity and non-insulin dependent type II diabetes mellitus. Am J Physiol 1982, 243: E15-30.
14. Kahn, C.R., Cretazz, M. Insulin receptors and the molecular mechanism of insulin action. Diabetes Metab Rev 1985, 1: 5-32.
15. Perseghin, G., Price, B.T., Petersen, F.K. et al. Increased glucose transport phosphorylation and muscle glycogen synthesis after exercise training in insulin resistant subjects. N Engl J Med 1996, 335: 1357-8.
16. Saltiel, A. R. Second messengers of insulin action. Diabetes Care 1990, 13: 244-56.
17. Kasuga, M., Fujita-Yamaguchi, Y., Blite, D.L. et al. Tyrosine specific protein kinase activity is associated with purified insulin receptor. Proc Natl Acad Sci USA 1983, 80: 2137-41.
18. Rosen, O.M. Banting Lecture 1989: Structure and function of insulin receptors. Diabetes 1989, 38: 1508-11.
19. Kahn, B., Cushman, S.W. Subcellular translocation of glucose transporters: Role of insulin action and its perturbation in altered metabolic states. Diabetes Metab Rev 1985, 1: 203-28.
20. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44: 1249-58.
21. Rudensski, A.S., Hadden, D.R., Atkinson, A.B. et al. Natural history of pancreatic islet beta-cell function in type 2 diabetes mellitus studied over six years by hemostasis model assessment. Diabet Med 1985, 5: 34-41.
22. Consoli, A., Nurjhan, N., Capani, F. et al. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989, 38: 550-7.
23. Turner, N.C. New therapeutic agents for the treatment of insulin resistance. Drug Discov Today 1996, 1: 109-16.
24. Moller, D.E. (Ed.). Insulin Resistance, First Edition. Wiley & Sons: West Sussex 1993.
25. Cheatham, B., Kahn, C.R. Insulin action and the insulin signaling network. Endocr Rev 1995, 16: 117-42.
26. Le Marchand-Brustel, Y. Molecular mechanisms of insulin action in normal and insulin-resistant states. Exp Clin Endocrinol Diabetes 1999, 107: 126-32.
27. Spiegelman, B.M. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47: 507-14.
28. Goldfine, I.D., Maddux, B.A. Yougren, J.F. Frittitta, L., Trischitta, V., Dohm, G.L. Membrane glycoprotein PC-1 and insulin resistance. Mol Cell Biochem 1998, 182: 177-84.
29. Paz, K., Hemi, R., LeRoith, D. et al. A molecular basis of insulin resistance. J Biol Chem 1997, 272: 29911-8.
30. Andres, R., Swerdloff, R., Pozefsky, T., Coleman, D. Manual feedback technique for the control of blood glucose concentration. In: Automation in Analytical Chemistry. Skeggs, LT. (Ed.). Mediad 1966, 486-91.
31. Bergman, R.N., Prager, R., Volund, A., Olefsky, J.M. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987, 79: 790-800.
32. Graci, S., Baratta, R., Degano, C. et al. The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities. J Endocrinol Invest 1999, 22: 472-5.
33. Gerich, J.E. Is muscle the major site of insulin resistance in type-2 (non-insulin-dependent) diabetes mellitus? Diabetologia 1991, 34: 607-10.
34. DeFronzo, R.A. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerosis. Neth J Med 1997, 50: 191-7.
35. Reaven, G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75: 473-86.
36. Beck-Nielsen, H., Hother-Neilson, O., Vaag, A., Alford, F. Pathogenesis of type-2 (non-insulin-dependent) diabetes mellitus: The role of skeletal muscle glucose uptake and hepatic glucose production in the development of hyperglycemia. A critical comment. Diabetologia 1994, 37: 217-21.
37. Zucker, L.M. Hereditary obesity in the rat associated with hyperlipidemia. Ann NY Acad Sci 1965, 131: 447-58.
38. Bray, G.A. The Zucker fatty rat: A review. Fed Proc 1977, 36: 148-53.
39. Fujiwara, T., Yoshioka, T., Ushiyama, I., Horikoshi, H. Characterization of new oral antidiabetic agent CS-045, studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988, 37: 1549-58.
40. Shafrir, E. Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 1992, 8: 179-208.
41. Nakamura, M., Yamada, K. Studies on a diabetic (KK) strain of the mouse. Diabetologia 1967, 3: 212-21.
42. Iwatsuka, H., Shino, A., Suzouki, Z. General survey of diabetic features of yellow KK mice. Endocrinol Japan 1970, 17: 23-35.
43. Russell, J.C., Ahuja, S.K., Manichawel, V., Rajotte, R.V., Amy, R.M. Insulin resistance and impaired glucose tolerance in atherosclerosis-prone LA/N-corpulent rat. Arteriosclerosis 1987, 7: 620-6.
44. Russell, J.C., Graham, S., Hameed, M. Abnormal insulin and glucose metabolism in JCR:LA-corpulent rat. Metabolism 1994, 43: 538-43.
45. Pederson, R.A., Campos, R.V., Buchan, A.M.J., Chishlom, C.B., Russell, J.C., Brown, J.C. Comparison of the enteroinsular axis in two strains of obese rat: The fatty Zucker and the JCR:LA-corpulent. Int J Obes 1991, 15: 461-70.
46. Kawano, K., Hirashima, T., Mari, S., Saitoh, Y., Kurosumi, M., Natori, T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992, 41: 1422-8.
47. Sato, T., Asahi, Y., Toide, K., Nakayama, N. Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a new model of NIDDM. Diabetologia 1995, 38: 1033-41.
48. Le Marchand-Brustel, Y., Freychet, P., Jeanrenaud, B. Longitudinal study on the establishment of insulin resistance in hypothalamic obese mice. Endocrinology 1978, 102: 74-85.
49. Le Marchand-Brustel, Y., Jeanrenaud, B., Freychet, P. Insulin binding and effects in isolated soleus muscle of lean and obese mice. Am J Physiol 1978, 234: E348-58.
50. Le Marchand-Brustel, Y., Olichan-Berthe, C., Gromeanx, T., Tanti, J.F., Rochet, N., Van Obderghen, E. Glucose transporter in insulin sensitive tissues of lean and obese mice. Effect of the thermogenic agent BRL 26830A. Endocrinology 1990, 127: 2687-95.
51. DeFronzo, R.A. Pharmacologic therapy for type-2 diabetes mellitus. Ann Intern Med 1999, 131: 281-303.
52. Reaven, G.M. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988, 37: 1595-607.
53. Yji-Jarvinen, H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995, 38: 1378-88.
54. Taylor, S.I., Accili, D., Imai, Y. Insulin resistance and insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994, 43: 735-40.
55. DeFronzo, R.A., Hendler, R., Simonsons, D. Insulin resistance is a prominent feature of insulin dependent diabetes. Diabetes 1982, 31: 795-801.
56. Golay, A., Chen, Y.D., Reaven, G.M. Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals. J Clin Endocrinol Metab 1986, 62: 1081-8.
57. Hollenbeck, C., Reaven, G.M. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987, 64: 1169-73.
58. Reaven, G.M. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75: 473-86.
59. Moller, D.E., Flier, J.S. Insulin resistance - Mechanisms, syndromes, and implications. N Engl J Med 1991, 335: 938-48.
60. Kahn, C.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994, 43: 1066-84.
61. Reaven, G.M., Hollenbeck, C.B., Chen, Y.D. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989, 32: 52-5.
62. Welborn, T.A., Breckenbridge, A., Rubinsten, A.H., Dollery, C.T., Fraser, T.R. Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1966, 1: 1336-7.
63. Reaven, G.M., Hoffman, B.B. A role for insulin in the aetiology and course of hypertension. Lancet 1987, 2: 435-6.
64. Reaven, G.M., Lithell, H., Landsberg, L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and sympathoadrenal system. N Engl J Med 1996, 334: 374-81.
65. Reaven, G.M. Insulin and hypertension. Clin Exp Hypertens 1990, 12: 803-16.
66. Tuck, M.L. Metabolic considerations in hypertension. Am J Hypertens 1990, 3: 355-65.
67. DeFronzo, R.A. The effect of insulin on renal metabolism. Diabetologia 1981, 21: 165-71.
68. Skott, P., Hother-Nielsen, O., Brunn, N.E. Effects of insulin on kidney function and sodium excretion in healthy subjects. Diabetologia 1989, 32: 550-7.
69. Endre, T. Insulin and renal sodium retention in hypertension-prone men. Hypertension 1994, 32: 694-9.
70. Minaker, K.L., Rowe, J.W., Young, J.B., Sparrow, D., Pallotta, J.A., Landsberg, L. Effect of age on insulin stimulation of sympathetic nervous system activity in man. Metabolism 1982, 31: 1181-4.
71. Hall, J.E. Obesity-associated hypertension. Hyperinsulinemia and renal mechanisms. Hypertension 1992, 19(Suppl.): 145-55.
72. Baron, A.D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 1993, 21: 129-35.
73. DeFronzo, R.A., Cooke, C.R., Adres, R., Faloona, G.R., Davis, P.J. The effect of insulin on renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975, 55: 845-55.
74. Rowe, J.W., Young, J.B., Minaker, K.L., Stevens, A.L., Pallotta, J., Landsberg, L. Effect of insulin and glucose infusions on the sympathetic nervous system activity in normal man. Diabetes 1981, 30: 219-25.
75. Christensen, N.J. Plasma norepinephrine and epinephrine in untreated diabetics during fasting and after insulin administration. Diabetes 1974, 23: 1-8.
76. Christlieb, A.R. Diabetics and hypertensive cardiovascular disease. Mechanisms and treatment. Am J Cardiol 1973, 32: 592-606.
77. Harrower, A.D.B. Cardiovascular diseases in diabetes mellitus. Br J Clin Pract 1977, 31: 47-51.
78. Mark, A.L. The sympathetic nervous system in hypertension: A potential long term regulator of hypertension. J Hypertens 1996, 5: 159-65.
79. Kaul, C.L. Role of sympathetic nervous system in experimental hypertension and diabetes mellitus. Clin Exp Hypertens 1999, 21: 95-112.
80. Kaul, C.L., Grewal, R.S. Increased urinary excretion of catecholamines and their metabolites in streptozotocin diabetic rats. Pharmacology 1980, 21: 223-8.
81. Lansberg, L., Young, J.B. Diet and the sympathetic nervous system: Relationship to hypertension. Int J Obes 1981, 5: 79-91.
82. Wright, D.W. Sucrose induced insulin resistance in the rat: Modulation by exercise and diet. Am J Clin Nutr 1983, 38: 879-83.
83. Kaul, C.L., Grewal, R.S. Vascular reactivity in streptozotocin induced diabetic rat. Pharmacol Res Commun 1980, 12: 945-58.
84. Folli, F., Saad, M.J.A., Velloso, L. et al. Cross-talk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999, 107: 133-9.
85. Shen, D.C., Shieh, S.M., Fuh, M.M.T., Wu, D.A., Chen, Y.D.I., Reaven, G.M. Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988, 66: 580-3.
86. Swislocki, A.L.M., Hoffman, B.B., Reaven, G.M. Insulin resistance, glucose tolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989, 2: 419-23.
87. Corry, D.B., Tuck, M.L. Glucose and insulin metabolism in hypertension. Am J Nephrol 1996, 16: 223-36.
88. Henriksen, E.J., Jacob, S., Post, D.L., Youngblood, E.B., Godicks, J. Antihypertensive agent moxonidine enhances glucose transport in insulin-resistant rats. Hypertension 1997, 30: 1560-5.
89. Molitch, M.E. Management of early diabetic nephropathy. Am J Med 1997, 102: 392-8.
90. O'Driscoll, G., Green, D., Rankin, J., Stanton, K., Taylor, R. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997, 100: 678-84.
91. Cabell, K.S., Ma, L., Johnson, P. Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. Biochem Pharmacol 1997, 54: 133-41.
92. Tang, Z., Shou, I., Wang, L.N., Fukul, M., Tomino, Y. Effects of antihypertensive drugs or glycemic control on antioxidant enzyme activities in spontaneously hypertensive rats with diabetes. Nephron 1997, 76: 323-30.
93. Higashiura, K., Ura, N., Miyazaki, Y., Shimamoto, K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999, 13(Suppl. 1): S71-4.
94. Lithell, H.O. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press 1998, Suppl. 3: 28-31.
95. Lachaal, M., Jung, C.Y. Insulin resistance and hypertension. Mol Cell Biochem 1992, 109: 119-25.
96. 2-adrenoceptor modulator celiprolol reduces insulin resistance in obese Zucker rats. Life Sci 1999, 64: 2071-9.
97. Sohda, T., Mizuno, K., Imamiya, E., Sugiyama, Y., Fujita, T., Kawamatsu, Y. Studies on antidiabetic agents II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull 1982, 30: 3580-600.
98. Spencer, C.M., Markham, A. Troglitazone. Drugs 1997, 54: 89-101.
99. Plosker, G.L., Faulds, D. Troglitazone. A review of its use in the management of type 2 diabetes mellitus. Drugs 1999, 57: 409-38.
100. Momose, Y., Meguro, K., Ikeda, H., Hatanaka, C., Oi, S., Sohda, T. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem Pharm Bull 1991, 39: 1440-5.
101. Hulin, B., Clark, D.A., Goldstein, S.W. et al. Novel thiazolidinediones as potent euglycemic agents. J Med Chem 1992, 35: 1853-64.
102. Balfour, J.A.B., Polsker, G.L. Rosiglitazone. Drugs 1999, 57: 921-30.
103. Inzucchi, S.E., Maggs, D.G., Spollett, G.R. et al. Efficiency and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998, 338: 867-72.
104. 2+ influx. J Endocrinol 1996, 150: 107-11.
105. Nakamura, Y., Ohya, Y., Onaka, U., Fuji, K., Abe, I., Fujishima, M. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 1998, 123: 675-82.
106. Strobel, A., Siquier, K., Zilberfarb, V., Strosberg, A.D., Issad, T. Effect of thiazolidinediones on expression of UCO2 and adipocyte markers in human PAZ 6 adipocytes. Diabetologia 1999, 42: 527-33.
107. Berger, J., Bailey, P., Biswas, C. et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996, 137: 4189-95.
108. Lister, C.A., Boam, D., Bretherton-Watt, D. et al. Rosiglitazone increases pancreatic islet area, number and insulin content but not gene expression. Diabetologia 1998, 41: A169.
109. Young, P.W., Cawthorne, M.A., Chyle, P.J. et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes: Association with increased insulin binding and cell surface GLUT4 as measured by photoaffinity labeling. Diabetes 1995, 44: 1087-92.
110. Wang, M., Wise, S.C., Left, T., Su, T-Z. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferatoractivated receptor γ. Diabetes 1999, 48: 254-64.
111. Walker, A.B., Chattington, P.D., Buckingham, R.E., Williams, G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999, 48: 1448-53.
112. Oakes, N.D., Kennedy, C.J., Jenkins, A.B. et al. A new antidiabetic agent, BRL 49653, reduces lipid bioavailability and improves insulin action and glucoregulation in the rat. Diabetes 1994, 43: 1203-10.
113. Oakes, N.D., Camilleri, S., Furler, S.M. et al The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 1997, 46: 935-42.
114. Olivers, W. Jr., Boneck, V., Wiard, R. et al. Responders and nonresponders: Treatment with thiazolidinedione insulin sensitizer, BRL 49653, improves diabetic dyslipidemia more than reducing hyperglycemia in ZDF rats. Diabetes 1996, 45(Suppl. 2): 316A.
115. Lefebvre, A.M., Peinado-Onsurbe, J., Leitersdorf, I. et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997, 17: 1756-64.
116. Buckingham, R.E., Al-Barazanji, K.A., Toseland, C.D.N. et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998, 47: 1326-34.
117. Digby, J.E., Montague, C.T., Sewter, C.P. et al. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998, 47: 138-41.
118. Sandouk, T., Reda, D., Hofmann, C. Antidiabetic agent pioglitazone enhances adipocytes differentiation of 3T3-F442A cells. Am J Physiol 1993, 264: C1600-8.
119. Klitzien, R.F., Clarke, S.D., Ulrich, R.G. Enhancement of adipocyte differentiation by insulin sensitizing agent. Mol Pharmacol 1992, 41: 393-8.
120. Chawla, A., Lazer, M.A. Peroxisome proliferator and retinoid signaling pathways coregulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 1994, 91: 1786-90.
121. Kallen, C.B., Lazar, M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3t3-L1 adipocytes. Proc Natl Acad Sci USA 1996, 93: 5793-6.
122. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkinson, W.O., Wilson, T.M., Khewar, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995, 270: 12953-6.
123. Arch, J.R.S., Ainsworth, A.T., Cawthorne, M.A. et al. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984, 309: 163-5.
124. Wilson, C., Wilson, S., Piercy, V., Sennitt, M.V., Arch, J.R. The rat lipolytic β-adrenoceptor: Studies using novel β-adrenoceptor agonists. Eur J Pharmacol 1989, 100: 309-19.
125. Thurblay, P.L., Ellis, R.D. Differences between the effects of noradrenaline and β-adrenoceptor agonist BRL 28410 in brown adipose tissue and hind limb of the anaesthetized rat. Can J Physiol Pharmacol 1986, 64: 1111-4.
126. 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 1997, 37: 421-50.
127. Henry, C., Buckert, A., Schutz, Y., Jequier, E., Felber, J.P. Comparison of thermogenic activity induced by the new sympathomimetic Ro 16-8714 between normal and obese subjects. Int J Obes 1988, 12: 227-36.
128. Golay, A., Felber, J.P., Jequier, E., DeFronzo, R.A., Ferrannini, E. Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 1988, 4: 727-47.
129. Challiss, R.A., Budohoski, L., Newsholme, E.A., Sennitt, M.V., Cawthorne, M.A. Effect of a novel thermogenesis β-adrenoceptor agonist (BRL 26830) on insulin resistance in soleus muscle from obese Zucker rats. Biochem Biophys Res Commun 1985, 128: 928-35.
130. 3 and atypical β-adrenoceptors. Med Res Rev 1993, 13: 663-729
131. Blin, N., Camoin, L., Maigret, B., Strosberg, A.D. Structural and conformational features determining selective signal transduction in the β3-adrenergic receptor. Mol Pharmacol 1993, 44: 1094-104.
132. Howe, R. β3-Adrenergic agonists. Drugs Fut 1993, 18: 529-49.
133. 3-adrenoceptors in a model of hypercholesterolemia. Farmaco 1999, 54: 710-2.
134. 3 adrenoceptor"? Trends Pharmacol Sci 1990, 11: 3-7.
135. Kordik, C.P., Reitz, A.B. Pharmacological treatment of obesity: Therapeutic strategies. J Med Chem 1999, 42: 181-201.
136. Zhang, B., Salituro, G., Szalkowski, D. et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284: 974-7.
137. Upton, R., Widdowson, P.S., Ishii, S., Tanaka, H., Williams, G. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker diabetic fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br J Pharmacol 1998, 125: 1708-14.
138. Reginato, M.J., Bailey, S.T., Krakow, S.L. et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 1998, 273: 32679-84.
139. Arakawa, K., Ishihara, T., Aoto, M., Inamasu, M., Saito, A., Ikezawa, K. Actions of novel antidiabetic thiazolidine, T-174, in animal models of non-insulin dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br J Pharmacol 1998, 125: 429-36.
140. Shinkai, H., Onogi, S., Tanaka, M. et al. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J Med Chem 1998, 41: 1927-33.
141. Shibata, T., Matsui, K., Yonemori, F., Wakitani, K. Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501. Eur J Pharmacol 1999, 373: 85-91.
142. Maegawa, H., Obata, T., Shibata, T. et al. A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Diabetologia 1999, 42: 151-9.
143. Shibata, T., Matsui, K., Nagao, K. et al. Pharmacological profile of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol 1999, 364: 211-9.
144. Shibata, T., Matsui, K., Yonemori, F. et al. JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models. Br J Pharmacol 1998, 125: 1744-50.
145. Shimaya, A., Noshiro, O., Hirayama, R., Yoneta, T., Niiigata, K., Shikama, H. Insulin sensitizer YM 268 ameliorates insulin resistance by normalising the decreased content of GLUT4 in adipose tissue of obese Zucker rats. Eur J Endocrinol 1997, 137: 693-700.
146. Lohray, B.B., Bhushan, V., Rao, B.P. et al. Novel euglycemic and hypolipidemic agents. 1. J Med Chem 1998, 41: 1619-30.